Healthcare ❯ Pharmaceuticals

Gene Therapy

Clinical Trials FDA Regulation Hemophilia Treatment Adverse Events Duchenne Muscular Dystrophy Cost of Treatment Regulatory Approval Patient Safety Rare Diseases

FDA Halts Rocket’s RP-A501 Gene Therapy for Danon Disease After Patient’s Death

The hold follows a fatal capillary leak syndrome event prompting scrutiny of a newly introduced immune suppression agent